BCG. Program Management. Vaccine Quality
|
|
- Osborn Webster
- 5 years ago
- Views:
Transcription
1 Program Management 50_16 To change from general to selective BCG vaccination, an efficient notification system must be in place in addition to the following criteria: an average annual notification rate of smear-positive pulmonary TB cases below 5 per ; or an average annual notification rate of tuberculous meningitis in children aged under five years below 1 per 10 million population during the previous five years; or an average annual risk of tuberculous infection below 0.1%. BCG vaccine (WHO position paper) Weekly Epid. Record (, 79: 27-38) Page 38 74_ As increasing numbers of industrialized countries are likely to consider shifting from routine to selective use of BCG during the next decade, the recommendations of IUATLD (International Union Against Tuberculosis and Lung Disease) are considered to be the appropriate guidelines for countries thinking of discontinuing BCG vaccination. Report of the Strategic Advisory Group of Experts (SAGE) - Geneva, June 2001 (WHO/V&B/02.07) Page 32 Vaccine Quality 81_ An ADT should be conducted on each lot of BCG vaccine. The number of CPs (culturable particles) in vaccine incubated at 37 C for 28 days should be not less than 20% of that in the vaccine stored at 4 C. Temperature sensitivity of vaccines WHO/IVB/06.XX Page June 2008 Page 1 of 15
2 50_8 The BCG vaccine should be manufactured according to the current recommendations published in the report of the WHO Expert Committee on Biological Standardization. BCG vaccine (WHO position paper) Weekly Epid. Record (, 79: 27-38) Page 28 14_ An ADT (accelerated degradation test) should be conducted on each lot of BCG vaccine. The number of culturable particles in vaccine incubated at 37 C for 28 days should be not less than 20% of that in the vaccine stored at 4 C Thermostability of vaccines WHO/GPV/98.07 Page 29 Cold Chain Equipment 14_ Experimental evidence indicates that (BCG vaccine) viability is unaffected by storage at -20 C or -30 C or by freezing and thawing up to 10 times. Thermostability of vaccines WHO/GPV/98.07 Page June 2008 Page 2 of 15
3 Vaccine Handling 81_ The recommended conditions for storing vaccines used in immunization programmes are shown in Appendix 81_1. This diagram also indicates the maximum times and temperatures in each case. At the higher levels of the cold chain, i.e., at national (primary), and regional or province level, OPV must be kept frozen between - 15oC and -25oC. Freeze-dried vaccines (i.e., BCG, measles, MMR and yellow fever) may also be kept frozen at -15oC to -25oC if cold chain space permits, but this is neither essential nor recommended. At other levels of the cold chain (intermediate vaccine stores and health facilities), these vaccines should be stored between +2oC and +8oC. All other vaccines should be stored at between +2oC and +8oC at all levels of the cold chain. Liquid formulations of vaccines containing diphtheria, pertussis, tetanus, hepatitis B, Haemophilus influenzae type b, IPV and their combinations should not be frozen. Temperature sensitivity of vaccines WHO/IVB/06.XX Page 2 81_ Reconstituted BCG vaccine is very unstable, must be kept cold, and must be discarded within six hours of reconstitution. The reasons for these precautions are as follows: 1.There is a risk of contamination because BCG vaccine, like other lyophilized live vaccines, does not contain any bacteriostatic agent. For this reason, WHO recommends that reconstituted lyophilized vaccine should be kept cold and discarded at the end of six hours. 2.There is a loss of potency. Once reconstituted, all BCG vaccines should be kept cold and discarded within six hours, regardless of how many doses remain in the vial or ampoule. Temperature sensitivity of vaccines WHO/IVB/06.XX Page 25 81_ Freeze-dried BCG vaccines, regardless of their substrain, are sensitive to ultraviolet and fluorescent light. They should be protected from light when used Temperature sensitivity of vaccines WHO/IVB/06.XX Page June 2008 Page 3 of 15
4 81_ Freeze-dried BCG vaccines, regardless of their substrain, are sensitive to ultraviolet and fluorescent light. They should be protected from light when used Temperature sensitivity of vaccines WHO/IVB/06.XX Page 25 17_ WHO recommended vaccine storage conditions (Appendix 17_3). WHO-UNICEF effective vaccine store management initiative: Modules 1-4 WHO/IVB/ Page 1:3 17_ WHO no longer recommends that freezedried vaccines (measles, yellow fever, Hib and BCG) be shipped and stored at -20 C. Storing them at -20 C is not harmful but is unnecessary. Instead, these vaccines should be stored and transported at +2 C to +8 C. WHO-UNICEF effective vaccine store management initiative: Modules 1-4 WHO/IVB/ Page 1:3 2_10 Administration summary: BCG vaccine (see Appendix 2_10) Immunization in practice: a practical resource guide for Health workers update Module 2: The vaccines Page 14 2_30 BCG vaccine: _ It is essential that only the diluent supplied with the vaccine be used. _ BCG vaccine should be kept at 2 C-8 C after reconstitution. _ Any remaining reconstituted vaccine must be discarded after six hours or at the end of the immunization session, whichever comes first. Immunization in practice: a practical resource guide for Health workers update Module 2: The vaccines Page June 2008 Page 4 of 15
5 3_20 BCG, measles, MR, MMR and rubella vaccines are equally sensitive to light (as well as to heat). Normally, these vaccines are supplied in vials made from dark brown glass, which gives them some protection against light damage, but care must still be taken to keep them covered and protected from strong light at all times. Immunization in practice: a practical resource guide for Health workers update Module 3: The cold chain Page 28 31_ At the higher levels of the cold chain, i.e. at the national (central) and regional or provincial levels, OPV must be kept frozen between -15 C and -25 C. Freeze-dried vaccines, i.e. BCG, measles, MMR and yellow fever vaccines, may also be kept in this temperature range (-15 C and -25 C) if there is sufficient space in the cold chain, but this is neither essential nor recommended. At other levels of the cold chain these vaccines should be stored between +2 C and +8 C. All other national immunization service vaccines should be stored between +2 C and +8 C at all levels of the cold chain. Ensuring the quality of vaccines at country level: Guidelines for health staff WHO/V&B/02.16 Page 13 29_ Reconstituted BCG, measles and yellow fever vaccines must be kept cooled and must be discarded after 6 hours after reconstitution. Proper handling and reconstitution of vaccines avoids programme errors V&B update 34 Page 1 29_ It is no longer necessary to ship and store freeze-dried vaccines (measles, yellow fever and BCG) at 20 C. Instead, they may be refrigerated at +2 to +8 C. Proper handling and reconstitution of vaccines avoids programme errors V&B update 34 Page 1 29_ WHO no longer recommends that freeze-dried vaccines (measles, yellow fever, Hib and BCG) be shipped and stored at 20 C. Storing them at 20 C is not harmful but is unnecessary and uses up valuable storage space in the deep-freeze. Instead, they should be kept in refrigeration and transported at +2 to +8 C. Proper handling and reconstitution of vaccines avoids programme errors V&B update 34 Page 2 27 June 2008 Page 5 of 15
6 14_ Freeze-dried BCG vaccines, regardless of their substrain, are sensitive to ultraviolet and fluorescent light. They should be packed in ampoules made from a substance of low light transmittance, such as amber glass, and should be protected from light when used. Thermostability of vaccines WHO/GPV/98.07 Page 34 14_ Reconstituted BCG vaccine is very unstable and should be used during one working session of five to six hours. Residual vaccine should be discarded at the end of the session. Thermostability of vaccines WHO/GPV/98.07 Page 34 14_ Reconstituted vaccines against measles, yellow fever and tuberculosis (BCG) are unstable vaccines; they should be used as soon as possible after reconstitution, be kept in a ice bath during the immunization session and should be discarded at the end of the session. Thermostability of vaccines WHO/GPV/98.07 Page 48 Multi-dose Open Vials 6_27 Opened vials of measles, yellow fever and BCG vaccines MUST be discarded at the end of each immunization session or after 6 hours whichever comes first. Immunization in practice: a practical resource guide for Health workers update Module 6: Holding an immunization session Page June 2008 Page 6 of 15
7 16_ Opened vials of measles, yellow fever, BCG and freeze-dried Hib vaccine cannot be used after an intial immunization session, (even if the VVM has not reached the discard point.). They must be discarded within six hours of reconstitution or at the end of the session, whichever comes first. The VVMs for these vaccines are attached to the vial caps and should be discarded when the vaccine is being reconstituted. Getting started with vaccine vial monitors WHO/V&B/02.35 Page 15 26_ The revised (multi-dose vial) policy does not change recommended procedures for handling vaccines that must be reconstituted, that is, BCG, measles, yellow fever, and some formulations of Hib vaccines. Once they are reconstituted, vials of these vaccines must be discarded at the end of each immunization session or at the end of six hours, whichever comes first. The use of opened multi-dose vials of vaccine in subsequent immunization sessions (WHO Policy Statement) WHO/V&B/00.09 Page 7 Schedule 84_ Since 1974, BCG vaccination has been included in the WHO Expanded Programme on Immunization (EPI) State of the art of new vaccines: research and development WHO/IVB/06.01 Page 31 39_ WHO recommends the following schedule for infants (Appendix 39_5). Vaccine introduction guidelines. Adding a vaccine to a national immunization programme: decision and implementation WHO/IVB/05.18 Page June 2008 Page 7 of 15
8 71_ The regularly-reviewed EPI policy recommendation for BCG is to continue the use of the vaccine as it prevents severe TB in some, but not all children who have been immunized. There should be no BCG booster doses. Should countries, based on cost-effectiveness considerations, decide to discontinue the use of BCG, WHO recommends applying the criteria defined by the International Union against Tuberculosis and Lung Disease (IUATLD). The criteria essentially refer to the requirement for an efficient case-notification system against a background of very low national prevalence figures for all forms of TB. Report of the Strategic Advisory Group of Experts (SAGE) - Geneva, October WHO/IVB/05.03 Page 24 1_14 Immunization of infants with Bacille Calmette-Guérin vaccine (BCG) can protect against TB meningitis and other severe forms of TB in children less than five years old. BCG vaccine is not recommended after 12 months of age because the protection provided is variable and less certain. The recommended method of prevention for children who are younger than 12 months old is to immunize them as soon after birth as possible with BCG vaccine. Immunization in practice: a practical resource guide for Health workers update Module 1: Target diseases Page 23 2_19 Typical immunization schedule for children (see Appendix 2_19.) Immunization in practice: a practical resource guide for Health workers update Module 2: The vaccines Page 24 6_13 If the infant does not have a scar and you cannot determine whether a dose of BCG has been given, immunize the infant with BCG vaccine. Immunization in practice: a practical resource guide for Health workers update Module 6: Holding an immunization session Page June 2008 Page 8 of 15
9 50_1 Unfortunately, the (BCG) vaccine does not fully meet the essential requirement of having a significant impact against the most common manifestation of TB, namely pulmonary disease. Despite the shortcomings of this vaccine, WHO continues to recommend that a single dose of BCG be given to neonates or as soon as possible after birth in countries with a high prevalence of TB. BCG vaccine (WHO position paper) Weekly Epid. Record (, 79: 27-38) Page 37, 38 50_2 Since severe adverse effects of BCG vaccination are extremely rare even in asymptomatic, HIV-positive infants, all healthy neonates should be BCG-vaccinated, even in areas endemic for HIV. However, where resources permit, long-term follow-up of BCG-vaccinated infants of known HIV-positive mothers is desirable for early treatment, should disseminated BCG disease occur in children with rapid development of immunodeficiency. BCG vaccine (WHO position paper) Weekly Epid. Record (, 79: 27-38) Page 28 50_4 In cases where infants have been exposed to smear-positive pulmonary TB shortly after birth, BCG vaccination should be delayed until completion of 6 months of prophylactic isoniazid treatment. BCG vaccine (WHO position paper) Weekly Epid. Record (, 79: 27-38) Page 28 50_5 Countries with a low burden of TB may choose to limit BCG vaccination to neonates and infants of recognized high-risk groups for the disease or to skin-testnegative older children. In some low-burden populations, BCG vaccination has been largely replaced by intensified case detection and supervised early treatment. BCG vaccine (WHO position paper) Weekly Epid. Record (, 79: 27-38) Page 28 50_7 There is no proven benefit of repeated BCG vaccination against TB. This also applies to revaccination of BCG-vaccinated individuals who remain negative by subsequent tuberculin testing. BCG vaccine (WHO position paper) Weekly Epid. Record (, 79: 27-38) Page 28 & June 2008 Page 9 of 15
10 50_11 In the absence of a scar in children in high-burden countries, BCG vaccination is indicated. BCG vaccine (WHO position paper) Weekly Epid. Record (, 79: 27-38) Page 34 50_12 In low-burden countries, good protection against primary TB may also be achieved following vaccination of skin-test-negative adults. BCG vaccination of skintestpositive individuals, whether induced by environmental mycobacteria, Mtb or BCG does not improve immunity to TB. BCG vaccine (WHO position paper) Weekly Epid. Record (, 79: 27-38) Page 36 50_13 BCG vaccination is indicated for all infants living in areas where TB is highly endemic (concerning HIV, see below); for infants and children at particular risk of TB exposure in otherwise low-endemic areas; for persons exposed to multidrug-resistant Mtb (impact not established.) BCG vaccination is contraindicated for persons with impaired immunity (symptomatic HIV infection, known or suspected congenital immunodeficiency, leukaemia, lymphoma or generalized malignant disease); for patients under immunosupressive treatment (corticosteroids, alkylating agents, antimetabolites, radiation); in pregnancy. BCG vaccine (WHO position paper) Weekly Epid. Record (, 79: 27-38) Page 36 50_15 Given the high risk of acquiring TB and the low risk of serious adverse events following BCG vaccination of HIV-exposed neonates, WHO maintains that, in HIVinfected areas, all neonates be given BCG. Older infants or children suspected of being HIV-infected should not be vaccinated if they have symptomatic disease or other evidence of immunosuppression. BCG vaccine (WHO position paper) Weekly Epid. Record (, 79: 27-38) Page June 2008 Page 10 of 15
11 79_5 There are few population-based data on the effectiveness, or otherwise, of BCG vaccine in preventing severe tuberculosis in HIV-positive infants. Given the high prevalence of HIV and tuberculosis in certain countries and of the current development of new tuberculosis vaccines, some of which are based on BCG, GACVS advises no change in the current recommendations for BCG immunization of infants in countries with a high prevalence of tuberculosis and that population-based studies should be undertaken to determine the efficacy and safety of BCG and related vaccines in HIV-negative and HIV-positive children in countries with a high endemic rate of tuberculosis. Global Advisory Committee on Vaccine Safety, 3 4 December 2003 Weekly Epid. Record (, 79: 16-20) Page 19 74_ SAGE strongly endorses the continued used of BCG in national immunization services as a means of minimizing the harmful effects of tuberculosis infection in the first year of life. SAGE recommends that the vaccine be used until there is an alternative improved anti-tuberculosis vaccine. In the meantime, national immunization services are encouraged to maintain the highest possible coverage of infants. SAGE reinforces WHO s recommendation that no booster dose of BCG be given, as there is no evidence that booster doses are efficacious. Report of the Strategic Advisory Group of Experts (SAGE) - Geneva, June 2001 (WHO/V&B/02.07) Page 32 Vaccine Administration 6_19 See Appendix 6_19 for chart entitled, "Administering vaccines to infants" BCG, DTP, DTP-HepB, HepB, measles, yellow fever, OPV" Immunization in practice: a practical resource guide for Health workers update Module 6: Holding an immunization session Page 19 50_10 WHO recommends intradermal application of the (BCG) vaccine, preferably on the deltoid region of the arm using syringe and needle, although other application methods such as the multiple puncture technique are practised in some countries. Newborn vaccinees normally receive half the dose given to older children. BCG vaccine can be given simultaneously with other childhood vaccines. BCG vaccine (WHO position paper) Weekly Epid. Record (, 79: 27-38) Page June 2008 Page 11 of 15
12 Contraindications 2_20 All infants should be immunized except in these three rare situations: 1. Anaphylaxis or a severe hypersensitivity reaction is an absolute contraindication to subsequent doses of a vaccine. Persons with a known allergy to a vaccine component should not be vaccinated. 2. Do not give BCG or yellow fever vaccine to an infant that exhibits the signs and symptoms of AIDS. Immunization in practice: a practical resource guide for Health workers update Module 2: The vaccines Page 24 6_11 All infants should be immunized except in these three rare situations: 1. Anaphylaxis or a severe hypersensitivity reaction is an absolute contraindication to subsequent doses of a vaccine. Persons with a known allergy to a vaccine component should not be vaccinated. 2. Do not give BCG or yellow fever vaccine to an infant who exhibits the signs and symptoms of AIDS (see Appendix 6_11A). Other vaccines should be given. 3. If a parent strongly objects to an immunization for a sick infant, do not give it. Ask the mother to come back when the infant is well. The following are not contraindications. Infants with these conditions should be immunized (see Appendix 6_11B) Immunization in practice: a practical resource guide for Health workers update Module 6: Holding an immunization session Page 12 50_3 Infants and children with symptomatic human immunodeficiency virus (HIV) or those known to have other immunodeficiency states should not be BCGvaccinated. BCG vaccine (WHO position paper) Weekly Epid. Record (, 79: 27-38) Page June 2008 Page 12 of 15
13 50_13 BCG vaccination is indicated for all infants living in areas where TB is highly endemic (concerning HIV, see below); for infants and children at particular risk of TB exposure in otherwise low-endemic areas; for persons exposed to multidrug-resistant Mtb (impact not established.) BCG vaccination is contraindicated for persons with impaired immunity (symptomatic HIV infection, known or suspected congenital immunodeficiency, leukaemia, lymphoma or generalized malignant disease); for patients under immunosupressive treatment (corticosteroids, alkylating agents, antimetabolites, radiation); in pregnancy. BCG vaccine (WHO position paper) Weekly Epid. Record (, 79: 27-38) Page 36 50_14 HIV-positive infants may receive BCG vaccine only when asymptomatic and living in areas where TB is highly endemic. Long-term follow-up of such children following vaccination is desirable. HIV-positive, asymptomatic infants in low-burden areas should not be BCG-vaccinated. Indications for vaccination of groups likely to contract HIV should always be considered carefully. The efficacy of BCG vaccination in HIV-infected infants is not known. BCG vaccine (WHO position paper) Weekly Epid. Record (, 79: 27-38) Page 36 50_15 Given the high risk of acquiring TB and the low risk of serious adverse events following BCG vaccination of HIV-exposed neonates, WHO maintains that, in HIVinfected areas, all neonates be given BCG. Older infants or children suspected of being HIV-infected should not be vaccinated if they have symptomatic disease or other evidence of immunosuppression. BCG vaccine (WHO position paper) Weekly Epid. Record (, 79: 27-38) Page June 2008 Page 13 of 15
14 79_5 There are few population-based data on the effectiveness, or otherwise, of BCG vaccine in preventing severe tuberculosis in HIV-positive infants. Given the high prevalence of HIV and tuberculosis in certain countries and of the current development of new tuberculosis vaccines, some of which are based on BCG, GACVS advises no change in the current recommendations for BCG immunization of infants in countries with a high prevalence of tuberculosis and that population-based studies should be undertaken to determine the efficacy and safety of BCG and related vaccines in HIV-negative and HIV-positive children in countries with a high endemic rate of tuberculosis. Global Advisory Committee on Vaccine Safety, 3 4 December 2003 Weekly Epid. Record (, 79: 16-20) Page 19 Adverse Event 76_ The (GACVS) concluded that the isolation and identification of a low level of isoniazid resistance of BCG strains from 5 patients presenting with lymphadenitis do not justify a change in standard policy. Global Advisory Committee on Vaccine Safety, 9 10 June 2005 Weekly Epid. Record (2005, 80: ) Page 10_ All immunization programmes should monitor at least the following AEFIs: (1) All injection site abscesses. (2) All cases of BCG lymphadenitis (3) All deaths that are thought by health workers, or the public, to be related to immunization. (4) All cases requiring hospitalization that are thought by health workers, or the public, to be related to immunization. (5) Other severe or unusual medical incidents that are thought by health workers, or the public, to be related to immunization. With respect to the third, fourth, and fifth events, health workers may relate the event to immunization because it occurred within a month of an immunization, as its case definition indicates. However, some medical incidents can be related to immunization even if they have a delayed onset. Surveillance of Adverse Events Following Immunization WHO/EPI/TRAM/ Rev 1 Page June 2008 Page 14 of 15
15 10_ For mild problems, health workers should comfort and advise parents and treat the patient. It is not necessary to report these reactions, except for BCG lymphadenitis and injection site abscesses, unless parents' concerns are significant. Surveillance of Adverse Events Following Immunization WHO/EPI/TRAM/ Rev 1 Page 11 Research 50_9 Improved TB vaccines are widely seen as a key element for successful TB control, and the development of efficient, safe and affordable vaccines against TB must remain a global priority. BCG vaccine (WHO position paper) Weekly Epid. Record (, 79: 27-38) Page 28 79_5 There are few population-based data on the effectiveness, or otherwise, of BCG vaccine in preventing severe tuberculosis in HIV-positive infants. Given the high prevalence of HIV and tuberculosis in certain countries and of the current development of new tuberculosis vaccines, some of which are based on BCG, GACVS advises no change in the current recommendations for BCG immunization of infants in countries with a high prevalence of tuberculosis and that population-based studies should be undertaken to determine the efficacy and safety of BCG and related vaccines in HIV-negative and HIV-positive children in countries with a high endemic rate of tuberculosis. Global Advisory Committee on Vaccine Safety, 3 4 December 2003 Weekly Epid. Record (, 79: 16-20) Page June 2008 Page 15 of 15
Measles. Phases of accelerated measles control activities (measles mortality reduction and measles elimination) are indicated in Appendix 80_5.
Program Management 80_1 With renewed global commitment to achieving measles mortality reduction, the 2003 World Health Assembly stressed the importance of achieving the goals adopted by the United Nations
More informationFREEZE - DRIED GLUTAMATE BCG VACCINE (JAPAN) FOR INTRADERMAL USE
(For The Medical Profession) FREEZE - DRIED GLUTAMATE BCG VACCINE (JAPAN) FOR INTRADERMAL USE DESCRIPTION It is a live freeze - dried vaccine made from an attenuated strain of Mycobacterium bovis. It is
More informationMODEL INSERT MEASLES, MUMPS AND RUBELLA (MMR) COMBINED VACCINE
MODEL INSERT MEASLES, MUMPS AND RUBELLA (MMR) COMBINED VACCINE DESCRIPTION The vaccine is a freeze-dried powder containing three viruses - measles, mumps and rubella. a) The measles vaccine component is
More informationPertussis. (Whole-cell pertussis vaccines) must not be frozen, but stored at 2 8 C. All wp vaccines have an expiry date of months.
Program Management 61_5 The wp vaccines have a considerably lower price than ap vaccines and, where resources are limited and the vaccine is well accepted by the local population, wp vaccine remains the
More informationExpanded Programme on Immunization (EPI):
Expanded Programme on Immunization (EPI): Introduction Four to five million annual deaths could be prevented by 2015 through sustained and appropriate immunization efforts, backed by financial support.
More informationThis document was published by: The National Department of Health. Editorial team: Provincial EPI Team National EPI Team Dr NJ Ngcobo
REVISED : OCTOBER 2010 This document was published by: The National Department of Health Editorial team: Provincial EPI Team National EPI Team Dr NJ Ngcobo Copies may be obtained from: The National Department
More informationInfluenza. Influenza vaccines (WHO position paper) Weekly Epid. Record (2005, 80: ) 287
Program Management 82_19 SAGE encouraged all countries to consider their preparedness for a potential influenza pandemic, recognizing that it would occur before strain-specific vaccine can be made in significant
More informationSelected vaccine introduction status into routine immunization
Selected introduction status into routine infant immunization worldwide, 2003 This report summarizes the current status of national immunization schedules in 2003, as reported by Member States in the /UNICEF
More informationPentabio Vaccine (DTP-HB-Hib)
SUMMARY OF PRODUCT CHARACTERISTICS Product Name Pharmaceutical Form Strength Presentation : Pentabio : Suspension for injection : 1, 5 and 10 doses : Box of 10 vials @ 0.5 ml Box of 10 vials @ 2.5 ml Box
More informationWHO Recommendations and Guidelines for the Prevention of Perinatal Hepatitis B and Use of Hepatitis B Vaccines
WHO Recommendations and Guidelines for the Prevention of Perinatal Hepatitis B and Use of Hepatitis B Vaccines Steven Wiersma,, Medical Officer WHO/EPI EPI,, Geneva March, 2006 Epidemiology Strategy WHO
More informationSummary of Key Points WHO Position Paper on BCG Vaccine, February 2018
Summary of Key Points WHO Position Paper on BCG Vaccine, February 2018 1 Introduction This position paper replaces the 2004 WHO position paper on Bacille Calmette-Guérin (BCG) vaccine and the 2007 WHO
More informationIntroduction of Haemophilus influenzae type b vaccine into immunization programmes
WHO/V&B/00.05 ORIGINAL: ENGLISH DISTR.: GENERAL Introduction of Haemophilus influenzae type b vaccine into immunization programmes Management guidelines, including information for health workers and parents
More informationEXPANDED PROGRAM OF IMMUNIZATION (EPI) Definition Program adopted by WHO since l974, it includes child immunization & vaccination of pregnant women.
EXPANDED PROGRAM OF IMMUNIZATION (EPI) Definition Program adopted by WHO since l974, it includes child immunization & vaccination of pregnant women. Strategy A. Child immunization Egyptian immunization
More informationTemperature monitors for vaccines and the cold chain
WHO/V&B/99.15 ORIGINAL: ENGLISH DISTR.: GENERAL Temperature monitors for vaccines and the cold chain Cold-chain monitor Vaccine vial monitor Freeze Watch TM Stop!Watch TM DT and TT shipping indicator DEPARTMENT
More informationVACCINE MANAGEMENT. Recommendations for Handling and Storage of Selected Biologicals. January 2001 DEPARTMENT OF HEALTH AND HUMAN SERVICES
VACCINE MANAGEMENT Recommendations for Handling and Storage of Selected Biologicals January 2001 DEPARTMENT OF HEALTH AND HUMAN SERVICES DTaP: Diphtheria Toxoid, Tetanus Toxoid, Acellular Pertussis Vaccine
More informationTravel. Program Management. Schedule
Program Management 69_4 YF (yellow fever) vaccine should be offered to all travellers to and from at-risk areas, unless they belong to the group of individuals for whom YF vaccination is contraindicated.
More informationSUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE MEDICINAL PRODUCT Diphtheria, Tetanus and Pertussis Vaccine (Adsorbed) I.P. Injectable, Suspension for injection. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 0.5 ml contains:
More informationSurveillance of adverse events following immunization
WHO/EPI/TRAM/93.02 REV.1 ORIGINAL: ENGLISH DISTR.: GENERAL Surveillance of adverse events following immunization Field guide for managers of immunization programmes GLOBAL PROGRAMME FOR VACCINES AND IMMUNIZATION
More informationSUMMARY OF PRODUCT CHARACTERISTICS
Registration No. 1B 12/46 Importer / Manufacturer: GPO-MBP SUMMARY OF PRODUCT CHARACTERISTICS 1. ME OF THE MEDICAL PRODUCT ORAL POLIOMYELITIS VACCINE 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One vaccine
More informationImmunisation. Objectives. Immunity is the protection which the body develops against further damage by an organism or toxin.
2 Immunisation Objectives When you have completed this unit you should be able to: Define immunisation. Write the immunisation schedule. Understand the advantages of immunisation. List the contraindications
More informationThe Gates Challenge. Bill Gates Commencement Address Harvard University Class of 2007
History & Future of the Expanded Programme on Immunization Supplier Meeting, Copenhagen, 3-4 April 2008 Dr Osman David Mansoor Senior Adviser EPI (New Vaccines) UNICEF New York The Gates Challenge If we
More informationCHILDHOOD VACCINATION
EPI (3) Age of Child How and Where is it given? CHILDHOOD VACCINATION Nicolette du Plessis Block 10 28/02/2012 10 weeks DTaP-IPV/Hib (2) Diphtheria, Tetanus, Acellular pertussis, Inactivated polio vaccine,
More informationBCG in Tower Hamlets. Luise Dawson Public Health Nurse
BCG in Tower Hamlets Luise Dawson Public Health Nurse Coverage levels of BCG for infants under 1 year 100% 90.9% 95.5% 95.0% 98.7% 90% 81% 82% 80% 70% 60% 50% 40% 30% 20% 10% 0% March 0708 March 0809 March
More informationProgram: Expanding immunization coverage for children
1 of 7 05/04/2012 20:51 Published on GiveWell (http://givewell.org) Home > Program: Expanding immunization coverage for children Program: Expanding immunization coverage for children In a nutshell The
More informationAfghanistan: WHO and UNICEF estimates of immunization coverage: 2017 revision
Afghanistan: WHO and UNICEF estimates of immunization coverage: 2017 revision July 7, 2018; page 1 WHO and UNICEF estimates of national immunization coverage - next revision available July 15, 2019 data
More informationPREVENTION OF TUBERCULOSIS. Dr Amitesh Aggarwal
PREVENTION OF TUBERCULOSIS Dr Amitesh Aggarwal 25 to 50 % of persons exposed to intimate contact with active PTB - latent infection with TB. Exposure to index case for 12 hours - high risk of infection.
More information3. Immunization safety
ORIGINAL : ENGLISH Training for mid-level managers (MLM) 3. Immunization safety Vaccine safety and quality Safe injections and waste disposal Immunization safety surveillance Immunization, Vaccines and
More informationHistory and aims of immunisation. Dr Anna Clarke Department of Public Health Dr. Steevens Hospital Dublin 8
History and aims of immunisation Dr Anna Clarke Department of Public Health Dr. Steevens Hospital Dublin 8 Objectives To examine the history of immunisation To explain the aim of immunisation To develop
More informationPakistan: WHO and UNICEF estimates of immunization coverage: 2017 revision
Pakistan: WHO and UNICEF estimates of immunization coverage: 2017 revision July 7, 2018; page 1 WHO and UNICEF estimates of national immunization coverage - next revision available July 15, 2019 data received
More information7. BCG Vaccination HSE/HPSC. Guidelines on the Prevention and Control of Tuberculosis in Ireland IUATLD criteria
7. BCG Vaccination The Bacillus Calmette-Guerin (BCG) vaccine was derived by in-vitro attenuation of the bovine tubercle bacillus between the years 1908 and 1918 in France. WHO encouraged widespread use
More informationAddendum to IPV Introduction Guidelines based on Recommendations of India Expert Advisory Group (IEAG)
Addendum to IPV Introduction Guidelines based on Recommendations of India Expert Advisory Group (IEAG) Background India was certified polio-free along with 10 other countries of WHO South-East Asia Region
More informationPreventing Accidental Freezing in the Cold Chain. An introduction to cold chain freezing and some options for reducing it.
Preventing Accidental Freezing in the Cold Chain An introduction to cold chain freezing and some options for reducing it. Program for Appropriate Technology in Health (PATH) 4/2003 Topics Presented Freezing
More informationSIXTY-SECOND WORLD HEALTH ASSEMBLY A62/22 Provisional agenda item April Viral hepatitis. Report by the Secretariat
SIXTY-SECOND WORLD HEALTH ASSEMBLY A62/22 Provisional agenda item 12.17 16 April 2009 Viral hepatitis Report by the Secretariat THE DISEASES AND BURDEN 1. The group of viruses that cause acute and/or chronic
More informationCOFM Immunization Policy
COUNCIL OF ONTARIO FACULTIES OF MEDICINE An affiliate of the Council of Ontario Universities COFM Immunization Policy This policy applies to all undergraduate medical students attending an Ontario medical
More information3 rd dose. 3 rd or 4 th dose, see footnote 5. see footnote 13. for certain high-risk groups
Figure 1. Recommended immunization schedule for persons aged 0 through 18 years 2013. (FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE [FIGURE 2]). These recommendations must be read
More informationExpanded Programme on Immunization (EPI)
Timor-Leste 217 Expanded Programme on Immunization (EPI) FACT SHEET Acronyms AD Auto disable MCV1 First dose measles containing vaccine AEFI Adverse events following immunization MCV2 Second dose measles
More informationTuberculosis and BCG
Tuberculosis and BCG Steve Graham Centre for International Child Health University of Melbourne Department of Paediatrics Royal Children s Hospital Melbourne Child Lung Health International Union Against
More informationSummary of product characteristics As per Annexure C. SUMMARY OF PRODUCT CHARACTERISTICS Doc. No. SPC/71108 Ver.1
Summary of product characteristics As per Annexure C SUMMARY OF PRODUCT CHARACTERISTICS Doc. No. SPC/71108 Ver.1 1. NAME OF THE MEDICINAL PRODUCT. ANNEXURE C to MODULE I Measles, Mumps & Rubella Vaccine
More informationExpanded Programme on Immunization (EPI)
Bhutan 2017 Expanded Programme on Immunization (EPI) FACT SHEET Acronyms AD Auto disable MCV1 First dose measles containing vaccine AEFI Adverse events following immunization MCV2 Second dose measles containing
More informationSummary of Key Points. WHO Position Paper on Vaccines against Hepatitis B, July 2017
Summary of Key Points WHO Position Paper on Vaccines against Hepatitis B, July 2017 1 Background l HBV is transmitted by exposure of mucosal membranes or non-intact skin to infected blood, saliva, semen
More informationImmunization in practice
WHO/IVB/XX ORIGINAL: ENGLISH Immunization in practice Module 1: Target diseases and vaccines Table of Contents About this module... 6 1. Diphtheria... 6 1.1 What is diphtheria?... 6 1.2 How is diphtheria
More informationCUSOM Student Health Immunization Requirements
CUSOM Student Health Immunization Requirements Regulatory and legislative authorities require that students demonstrate immunization, immunity and/or protection from multiple contagious diseases before
More informationExpanded Programme on Immunization (EPI)
Sri Lanka 217 Expanded Programme on Immunization (EPI) FACT SHEET Acronyms AD Auto disable MCV1 First dose measles containing vaccine AEFI Adverse events following immunization MCV2 Second dose measles
More informationC o n t e n t s. > Immunizations 4. > Diphtheria 6. > Pertussis 7. > Tetanus 8. > Polio 9. > Measles 10. > Tuberculosis 11.
C o n t e n t s > Immunizations 4 > Diphtheria 6 > Pertussis 7 > Tetanus 8 > Polio 9 > Measles 1 > Tuberculosis 11 > Hepatitis B 12 > Rubella and CRS 13 > Haemophius Influenza B 14 I m m u n i z a t i
More informationUpdated WHO position paper on pertussis vaccines. Geneva, Switzerland October 2010
Updated WHO position paper on pertussis vaccines Geneva, Switzerland October 2010 Introduction Replaces the position paper on pertussis vaccines published in the Weekly Epidemiological Record in January
More informationNigeria: WHO and UNICEF estimates of immunization coverage: 2017 revision
Nigeria: WHO and UNICEF estimates of immunization coverage: 2017 revision July 7, 2018; page 1 WHO and UNICEF estimates of national immunization coverage - next revision available July 15, 2019 data received
More informationSyrian Programme Refugees Advice on assessment of immunisation status and recommendations for additional immunisation
Syrian Programme Refugees Advice on assessment of immunisation status and recommendations for additional immunisation Background Information Immunisation services in Syria Syria had good immunisation services,
More informationExpanded Programme on Immunization (EPI)
Indonesia 217 Expanded Programme on Immunization (EPI) FACT SHEET Acronyms AD Auto disable MCV1 First dose measles containing vaccine AEFI Adverse events following immunization MCV2 Second dose measles
More informationOVERVIEW OF THE NATIONAL CHILDHOOD IMMUNISATION PROGRAMME IN SINGAPORE
OVERVIEW OF THE NATIONAL CHILDHOOD IMMUNISATION PROGRAMME IN SINGAPORE Dr Tiong Wei Wei, MD, MPH Senior Assistant Director Policy and Control Branch, Communicable Diseases Division Ministry of Health 9
More informationTuberculin Skin Testing
Understanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010 Testing to TB Infection Using the TST Presented by Debra Howenstine, MD for Debbie Onofre, RN October 5, 2010 Tuberculin
More informationUNICEF s perspective. WHO Informal Consultation to develop further guidance on vaccines for the UNEP-convened INC4 Geneva, 3-4 April 2012
UNICEF s perspective WHO Informal Consultation to develop further guidance on vaccines for the UNEP-convened INC4 Geneva, 3-4 April 2012 UNICEF procures immunization supplies on behalf of around 100 countries
More informationPriorix TM Measles, mumps and rubella vaccine (live, attenuated)
Priorix TM Measles, mumps and rubella vaccine (live, attenuated) QUALITATIVE AND QUANTITATIVE COMPOSITION Priorix is a lyophilised mixed preparation of the attenuated Schwarz measles, RIT 4385 mumps (derived
More informationPolio Vaccine Biological Page
Polio Vaccine Biological Page Section 7: Biological Product Information Standard #: 07.300 Created by: Approved by: Province-wide Immunization Program Standards and Quality Province-wide Immunization Program,
More informationWHO Guidance Note: Vaccine Diluents
WHO Guidance Note: Vaccine Diluents Revision 2015 THE PROPER HANDLING AND USE OF VACCINE DILUENTS This document was published by the Expanded Programme on Immunization of the Department of Immunization,
More informationNOTE: The above recommendations must be read along with the footnotes of this schedule.
Figure 1. Recommended immunization schedule for persons aged 0 through 18 years United States, 2014. (FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE [FIGURE 2]). These recommendations
More informationGlaxoSmithKline Biologicals Rotarix WHO PACKAGE INSERT. Rotarix TM 1 WHO Package insert
GlaxoSmithKline Biologicals Rotarix WHO PACKAGE INSERT Rotarix TM 1 WHO Package insert GlaxoSmithKline Biologicals Rotarix Method of administration Rotarix is for oral use only. ROTARIX SHOULD UNDER NO
More informationViral Hepatitis in Reproductive Health
Viral Hepatitis in Reproductive Health Training Course in Sexual and Reproductive Health Research Geneva 2010 Dr José M Bengoa Dr Pierre Jean Malè Consultants Division of Gastroenterology and Hepatology
More informationVaccine Storage in Remote Areas
Vaccine Storage in Remote Areas Lu Aye International Technologies Centre (IDTC) Department of Civil & Environmental Engineering The University of Melbourne lua@unimelb.edu.au The 2 nd Annual Nossal Global
More informationAdverse Event GACVS. Global Advisory Committee on Vaccine Safety, 910 June 2005
Adverse Event The Committee considered the decision taken by the Government of Japan on 30 May 2005 to suspend routine vaccination with the mouse brainderived Japanese encephalitis (JE) vaccine currently
More informationPrimary Vaccine Container Roundtable: Modeling
Primary Vaccine Container Roundtable: Modeling Bruce Y. Lee, MD, MBA Associate Professor of Medicine, Epidemiology, and Biomedical Informatics University of Pittsburgh HERMES Vision Data on Supply Chain
More informationNOTE: The above recommendations must be read along with the footnotes of this schedule.
Figure 1. Recommended immunization schedule for persons aged 0 through 18 years 2013. (FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE [FIGURE 2]). These recommendations must be read
More informationCOFM Immunization Policy 2016
COFM Immunization Policy 2016 Council of Ontario Faculties of Medicine June 2016 COUNCIL OF ONTARIO FACULTIES OF MEDICINE An affiliate of the Council of Ontario Universities COFM Immunization Policy 2016
More informationImmunization Guidelines for the Use of State Supplied Vaccine April 18, 2013
DTaP / DT DTaP/IPV/Hep B Combination (Pediarix ) Children from 6 weeks of age up to the 7 th birthday Children from 2 months of age up to the 7th birthday: Indicated for the primary doses of DTaP, IPV,
More informationGuideline for the immunization of HIV infected persons in Sri Lanka
DOI: http://doi.org/10.4038/joshhm.v3i0.64 Guideline for the immunization of HIV infected persons in Sri Lanka Dr. M. K. Darshanie Mallikarachchi, Consultant Venereologist, Provincial General Hospital
More informationHeat and Freeze Sensitivity of Vaccines
Heat and Freeze Sensitivity of Vaccines DCVMN Workshop "Vaccine quality management systems for manufacturing excellence" Michael Rush, MBA Executive Director - Global Health Policy October 24-25, 2013
More informationTable 1: Basic information Total population 25,030, (per 100,000 LB) Division/Province/State/Region 11. District 210
EPI history EPI launched in 980 HepB vaccine introduced in 003 AD syringes introduced in 003 HepB birth dose introduced in 004 DTP-HepB vaccine introduced in 006 MCV introduced in 008 DTP-Hib-HepB vaccine
More informationIMMUNIZATION(Vaccination)
IMMUNIZATION(Vaccination) 1 st week of age BCG OPV zero dose HBV 1 st dose 2 nd month of age 1 st dose DPT OPV HBV 2 nd ROTA Hib 1 st dose dose 1 st dose 1 st dose 4 th month of age DPT 2 nd dose OPV 2
More informationWhat DO the childhood immunization footnotes reveal? Questions and answers
What DO the childhood immunization footnotes reveal? Questions and answers Stanley E. Grogg, DO, FACOP, FAAP he Advisory Committee on Immunization Practices (ACIP) recommends the childhood vaccination
More informationThe Johns Hopkins Vaccine Initiative Johns Hopkins Bloomberg School of Public Health
WHO Internships (Terms of Reference) for VIEW Scholars Program January 2010 A. Examining approaches to collecting and analyzing HPV vaccine coverage data B. County level burden of disease estimates for
More informationHepatitis B vaccination of newborns in rural China: evaluation of an out-of-coldchain delivery strategy. Istanbul, Turkey March 15-17, 2006
Hepatitis B vaccination of newborns in rural China: evaluation of an out-of-coldchain delivery strategy Istanbul, Turkey March 15-17, 2006 Contents Introduction Objective Methods and Implementation Results
More informationIntroduction of Inactivated Polio Vaccine (IPV) in Routine Immunizations
Introduction of Inactivated Polio Vaccine (IPV) in Routine Immunizations A handbook for regional consultants, policy makers, and programme managers on policy and operational aspects related to introduction
More informationFor the use only of Registered Medical Practitioners or a Hospital or a Laboratory HIBERIX
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory HIBERIX Haemophilus type b conjugated vaccine IP 1. NAME OF THE MEDICINAL PRODUCT Haemophilus type b conjugated vaccine
More informationPolio vaccines and polio immunization in the pre-eradication era: WHO position paper. Published in WER 4 June, 2010
Polio vaccines and polio immunization in the pre-eradication era: WHO position paper Published in WER 4 June, 2010 Epidemiology & Background Poliomyelitis (polio) is an acute communicable disease of humans
More informationAppendix 7: Vaccine presentation, preparation, disposal, and needle-stick recommendations
Appendix 7: Vaccine presentation, preparation, disposal, and needle-stick recommendations A7.1 Presentation of vaccines Most of the vaccines in current use are supplied in prefilled syringes or vials.
More informationHealth Care Workers (HCWs) in Ireland should have 2 doses of MMR vaccine. Two of the cases in recent outbreaks in Ireland were HCWs.
This information should be read in conjunction with Immunisation Guidelines for Ireland available at http://bit.ly/niacguidelines Summary of Product Characteristics for MMR vaccines available at www.hpra.ie
More informationCity, University of London Institutional Repository
City Research Online City, University of London Institutional Repository Citation: Parmar, D., Baruwa, E.M., Zuber, P. & Kone, S. (2010). Impact of wastage on single and multi-dose vaccine vials: implications
More informationVaccines Prevent Illness
Vaccines Prevent Illness Vaccinations, also called immunizations, can prevent many illnesses that might otherwise make people sick or even cause death. Vaccines work by strengthening the body s immune
More informationTotal population 24,759,000. Live births (LB) 342,458. Children <1 year 337,950. Children <5 years 1,698,664. Children <15 years 5,233,093
DPR Korea 4 Immunization system highlights There is a comprehensive multiyear plan (cmyp) for immunization covering -5. A standing national technical advisory group on immunization (NTAGI) with formal
More informationPriorix TM Measles, mumps and rubella vaccine
Priorix TM Measles, mumps and rubella vaccine QUALITATIVE AND QUANTITATIVE COMPOSITION Priorix is a lyophilised mixed preparation of the attenuated Schwarz measles, RIT 4385 mumps (derived from Jeryl Lynn
More informationTable 1: Basic information (per 1,000 LB) 42.4 (per 1,000 LB) 49.7 (per 1,000 LB) 215 (per 100,000 LB)
EPI history EPI started in 978 EPI re-structured in March 000 DTP-HepB vaccine introduced in 007 DTP-Hib-HepB)vaccine introduced in 0 MR vaccine introduced in Feb 06 Second dose of MR introduced in Feb
More informationPrimary Vaccine Container Selection in Developing Countries Safety. Neal Halsey Johns Hopkins Bloomberg School of Public Heath
Primary Vaccine Container Selection in Developing Countries Safety Neal Halsey Johns Hopkins Bloomberg School of Public Heath Issues Requested to Cover 1. Rates of contamination, needlesticks, etc. due
More informationTotal population 1,265,308,000. Live births (LB) 27,016,000. Children <1 year 25,928,200. Children <5 years 23,818,000. Children <15 years 25,639,000
India 4 Immunization system highlights There is a comprehensive multiyear plan (cmyp) for immunization covering 3-7. National technical advisory group on immunization (NTAGI) exists and formal written
More informationCurrent National Immunisation Schedule Dr Brenda Corcoran National Immunisation Office.
Current National Immunisation Schedule 2012 Dr Brenda Corcoran National Immunisation Office Objectives To outline immunisation schedules in Ireland Primary childhood schedule Vaccine uptake rates School
More informationUse of Infanrix -IPV+Hib in the infant primary immunisation schedule
Use of Infanrix -IPV+Hib in the infant primary immunisation schedule An update for registered healthcare practitioners July 2014 Quality Education for a Healthier Scotland 1 Acknowledgments Many thanks
More information7.0 Nunavut Childhood and Adult Immunization Schedules and Catch-up Aids
7.0 Nunavut Childhood and Adult Immunization Schedules and Catch-up Aids Contents Introduction Nunavut Recommended Childhood Immunization Schedule Nunavut Routine Adult Immunization Schedule Nunavut Immunization
More informationImpact of wastage on single and multi-dose vaccine vials: Implications for introducing pneumococcal vaccines in developing countries
Human Vaccines ISSN: 1554-8600 (Print) 1554-8619 (Online) Journal homepage: http://www.tandfonline.com/loi/khvi19 Impact of wastage on single and multi-dose vaccine vials: Implications for introducing
More informationChildhood immunisation
Childhood immunisation Guidance notes for professionals 2011/12 edition the safest way to protect our children Consent Informed consent which can be either written or oral (depending on local Trust policy)
More informationMOBILISING COMMUNITIES FOR IMMUNIZATION SERVICES
MOBILISING COMMUNITIES FOR IMMUNIZATION SERVICES Photo of VHT conducting a community meeting What VHTs and community mobilisers need to know and do Printed with support from UNICEF and partners 2 1. Introduction
More informationFrequently asked questions (FAQs) on MR vaccination campaign
Frequently asked questions (FAQs) on MR vaccination campaign What are measles/rubella diseases? Measles is a highly infectious disease causing illness and death due to complications in the form of diarrhea,
More informationCyprus Experience. Dr. Elena Papamichael Ministry of Health
Cyprus Experience Dr. Elena Papamichael Ministry of Health Cyprus became independent on1960. On 1974, Turkish troops invaded in the island disturbing the willing for peaceful living. Since then, Turkey
More informationVaccines and immunization
^ и Л World Health Organization ^ ^ ^ ^ Organisation mondiale de la Santé EXECUTIVE BOARD Ninety-fifth Session Provisional agenda item 10 EB95/INF.DOC./7 19 October 1994 Vaccines and immunization Orientation
More informationGlobal update on temperature monitoring
Global update on temperature monitoring Why bother about temperature monitoring Objectives of the immunization supply chain Impacts of temperature excursions If undetected If detected Availability of vaccines
More informationImmunization Guidelines for the Use of State Supplied Vaccine May 17, 2015
DTaP / DT DTaP/IPV/Hep B Combination (Pediarix ) Children from 6 weeks of age up to the 7 th birthday Children from 2 months of age up to the 7th birthday: Indicated for the primary doses of DTaP, IPV,
More information6. Making a comprehensive annual national immunization plan and budget
ORIGINAL : ENGLISH Training for mid-level managers (MLM) 6. Making a comprehensive annual national immunization plan and budget Analyse data Interactive problemsolving Combine and integrate Check completeness
More informationBCG Vaccine. For Intradermal Injection
BCG Vaccine For Intradermal Injection Name of the medicine BCG VACCINE, Bacillus Calmette and Guérin Description BCG Vaccine (Bacillus Calmette-Guérin) is a freeze-dried live bacterial vaccine prepared
More informationFrom: New York State Department of Health, Bureau of Communicable Disease Control, Immunization Program
November 3, 2008 To: Hospitals, Providers, Local Health Departments From: New York State Department of Health, Bureau of Communicable Disease Control, Immunization Program HEALTH ADVISORY: USE OF PENTACEL
More information1. Executive Summary 2. Worldwide Pediatric Vaccines Market and Forecast ( ) 3. Worldwide Pediatric Vaccines Market Share & Forecast (Sector
1. Executive Summary 2. Worldwide Pediatric Vaccines Market and Forecast (2006 ) 3. Worldwide Pediatric Vaccines Market Share & Forecast (Sector wise) (2005 ) 4. Worldwide Pediatric Vaccines Market Share
More informationMeasles and Measles Vaccine
Measles and Measles Vaccine Epidemiology and Prevention of Vaccine- Preventable Diseases Note to presenters: Images of vaccine-preventable diseases are available from the Immunization Action Coalition
More informationSummary of the October 2017 meeting of the Strategic Advisory Group of Experts on Immunization
Summary of the October 2017 meeting of the Strategic Advisory Group of Experts on Immunization The Strategic Advisory Group of Experts (SAGE) on Immunization 1 met on 17-19 October 2017 in Geneva, Switzerland.
More information